JP5842304B2 - External patch - Google Patents

Description

  The present invention relates to an external patch, and more particularly, to an external patch comprising a support and a plaster layer containing a drug and an adhesive.

  Conventionally, external patches comprising a support, a paste layer containing a drug such as an anti-inflammatory drug, and a release liner have been widely known and manufactured and sold. In general, external patches are roughly classified into a cataplasm, which is a hydrous preparation, and a tape, which is a non-hydrous preparation, depending on the base component contained in the plaster layer. Most of the supports used in external patches are cloth base materials such as nonwoven fabric and knitted fabric (knit).

  On the other hand, a patch using a polyurethane film as a support is also known from the viewpoint of conspicuousness at the time of sticking. For example, JP 2006-104174 A (Patent Document 1) discloses a patch comprising a support formed by laminating a urethane resin layer and a fiber sheet layer, and a hydrous plaster. Japanese Patent Publication No. 7-116023 (Patent Document 2) discloses a patch having a polyurethane film having a thickness of 40 to 150 μm as a support and provided with an acrylic pressure-sensitive adhesive layer containing a drug.

  JP 2006-104174 A   Japanese Examined Patent Publication No. 7-116023

  The patch disclosed in Patent Document 1 is a poultice and has a thickness compared to a tape, so that it is applied to joints such as knees and elbows where bending and stretching are repeated, bedding and clothing When it is used while sleeping such that it can rub against the skin, there is a problem in terms of usability, such as the patch is not sufficiently adhered to the skin and is easily peeled off. Since the patch disclosed in Patent Document 2 uses a polyurethane film having a certain thickness as a support, there is a problem that it cannot be sufficiently satisfied from the viewpoint of sticking feeling (uncomfortable feeling), and further improvement is desired. It was rare.

  Further, since the external patch contains a drug such as an anti-inflammatory drug uniformly in the plaster layer, it is necessary to use a dissolving agent for dissolving the drug in some cases. For example, when a polyurethane film is used for the support, if a large amount of the dissolving agent is used, there is a risk of deterioration such as dissolution or deformation of the polyurethane film. In particular, the thinner the film, the more prominent the deterioration. Moreover, there is a possibility that the polyurethane film is deteriorated to some extent due to the influence of a drug or the like contained in the plaster layer. There was a problem in terms of the stability of the properties of the preparation, and further improvement was desired.

  The present invention has been made in view of the above circumstances, and is excellent in property stability of a preparation such as being sufficiently peeled off to the skin, having a good sticking feeling (no discomfort), and capable of suppressing deterioration of the support. An object is to provide an external patch.

  The inventors of the present invention conducted intensive research to achieve the above-mentioned object. As a result, a polyurethane film was used as a support, and monoterpenes were blended into a plaster layer containing a drug and an adhesive. It has been found that the present invention can provide an external patch excellent in property stability of a preparation that is difficult to peel off sufficiently to adhere to the skin, has a good feeling of sticking (no discomfort), and can suppress deterioration of the support. The invention has been completed. Specifically, the present invention provides the following.

(1) A support and a plaster layer laminated on the support,
The support is a polyurethane film;
The external patch, wherein the paste layer contains a drug, monoterpenes, and an adhesive.
(2) The external patch according to (1), wherein the support is a polyurethane film having a thickness of 5 to 30 μm.
(3) The external patch according to (1) or (2), wherein the total thickness of the support and the plaster layer is 10 to 60 μm.
(4) The adhesive for external use according to any one of (1) to (3), wherein the adhesive is at least one selected from a rubber adhesive, an acrylic adhesive, and a silicone adhesive.
(5) The adhesive for external use according to (4), wherein the adhesive is a rubber adhesive.
(6) The external patch according to (5), wherein the rubber-based adhesive is a styrene-isoprene-styrene block copolymer.
(7) The external patch according to any one of (1) to (6), wherein the drug is a non-steroidal anti-inflammatory agent.
(8) The external patch according to (7), wherein the non-steroidal anti-inflammatory agent is at least one selected from the group consisting of felbinac, diclofenac, loxoprofen, ketoprofen, and pharmacologically acceptable salts thereof. Agent.
(9) A support and a plaster layer laminated on the support,
The support is a polyurethane film having a thickness of 5 to 30 μm,
The total thickness of the support and the plaster layer is 10 to 60 μm,
The plaster layer contains a drug, l-menthol, and a styrene-isoprene-styrene block copolymer,
The external patch, wherein the drug is at least one selected from the group consisting of felbinac, diclofenac, loxoprofen, ketoprofen, and pharmacologically acceptable salts thereof.

  According to the present invention, it is possible to provide an external patch excellent in property stability of a preparation, such as being sufficiently close to the skin and not easily peeled off, having a good patch feeling (no discomfort), and capable of suppressing deterioration of a support. it can.

[External patch]
The external patch of the present invention is a patch that can be used as a pharmaceutical, a quasi-drug, or a cosmetic for applying to the skin, and comprises a support and a plaster layer laminated on the support. It is a patch. In general, external patches can be roughly classified into a cataplasm, which is a hydrous preparation, and a tape, which is a non-hydrous preparation, depending on the base component contained in the plaster layer. From the viewpoints of skin adhesion and adhesiveness depending on the thickness of the plaster layer, a tape is preferable.

[Support]
A polyurethane film is used for the support of the present invention. The polyurethane film is obtained by forming a polyurethane elastomer produced by reacting diisocyanate and polyol into a film, and can be produced by a known production method. The thickness of the polyurethane film is preferably 5 to 30 μm. If the thickness is less than 5 μm, it is difficult to produce a film or the strength is insufficient as a support, and if it exceeds 30 μm, the film cannot be sufficiently satisfied from the viewpoint of sticking feeling (uncomfortable feeling). Commercially available products can be used as the polyurethane film used in the support of the present invention, and examples include Mobilon film (trade name: Nisshinbo Chemical Co., Ltd.) and Klanger (trade name: Kurashiki Spinning Co., Ltd.). By using such a urethane film, it is possible to obtain an external patch with good adhesion feeling (no discomfort) that is not easily peeled off sufficiently to the skin. In addition, the external patch of the present invention has convenience such as waterproofness, and allows simple bathing.

[Carrier layer]
The external patch of the present invention is a carrier layer or the like on one side of a polyurethane film as a support for the purpose of improving the film forming property of the support, the handleability of the patch, and the adherence to an adherend. Additional layers can be provided. In this case, it can be prepared as a patch having a laminated structure of “carrier layer / support / plaster layer / liner”. For the carrier layer, for example, films made of various thermoplastic resins such as polyurethane, polyethylene, polypropylene, ionomer, polyamide, polyvinyl chloride, polyvinylidene chloride, ethylene vinyl acetate copolymer, thermoplastic polyester, polytetrafluoroethylene, etc. are used. It is preferable to form them. Various films may be laminated on paper. These carrier layers are desirably thicker or stronger than the polyurethane elastomer layer. The thickness of the carrier can be appropriately set, but is usually 10 μm or more, preferably 20 μm or more, and the upper limit is about 500 μm. Since the support and the paste layer are firmly bonded, the carrier layer can be easily peeled off during use.

[Plaster layer]
The plaster layer of the present invention contains a drug, monoterpenes, and an adhesive.

[Drug]
The drug used in the present invention is not particularly limited as long as it can be used as an external preparation. For example, felbinac, diclofenac, loxoprofen, ketoprofen, indomethacin, flurbiprofen, piroxicam, meloxicam, ketorolac, phenylbutazone, acetylsalicylic acid, flufenamic acid, mefenamic acid, ibuprofen, ampenac, fenbufen, or pharmacologically acceptable thereof Non-steroidal anti-inflammatory agents that are possible salts. Other drugs include, for example, cortisone acetate, dexamethasone acetate, dexamethasone, hydrocortisone acetate, hydrocortisone, prednisolone acetate, prednisolone, hydrocortisone butyrate, prednisolone acetate valerate, istipendyl hydrochloride, chlorpheniramine hydrochloride, chlorpheniramine maleate, diphenhydramine, hydrochloric acid Diphenhydramine, crotamiton, glycyrrhizic acid (and its salts), glycyrrhetinic acid, glycol salicylate, methyl salicylate, allantoin, isopropylmethylphenol, benzalkonium chloride, benzethonium chloride, calamine, zinc oxide, ethyl aminobenzoate, oxypolyethoxydodecane, Dibucaine, dibucaine hydrochloride, lidocaine, lidocaine hydrochloride, aqueous ammonia, tocophero , And tocopherol acetate or panthenol, it is. Preferably, the non-steroidal anti-inflammatory agent, more preferably at least one selected from the group consisting of felbinac, diclofenac, loxoprofen, ketoprofen, and pharmacologically acceptable salts thereof. The content of the drug is not particularly limited, but is generally 0.1 to 20% by weight with respect to the entire plaster.

[Monoterpenes]
The external patch according to the present invention contains monoterpenes in the plaster layer. By blending monoterpenes, the deterioration of the polyurethane film due to the influence of the drug and its solubilizer can be suppressed, and the drug can be uniformly contained in the plaster layer. That is, by blending monoterpenes, the amount of solubilizer used to dissolve the drug can be reduced, and furthermore, the monoterpenes can be used as a drug solubilizing agent. Can be prevented, and at the same time, the precipitation of drugs and the like in the plaster layer can be suppressed. By this, it can be set as the external patch which is excellent in the property stability of a formulation.

  Monoterpenes used in the present invention are not particularly limited as long as they are monoterpenes usually used in pharmaceuticals, quasi drugs, and cosmetics. For example, menthol, camphor, borneol, eugenol, cineol, thymol, bisabolol, α- Pinene or limonene can be exemplified. Menthol or camphor is preferable, and menthol is more preferable. These monoterpenes can be used as natural products or synthetic products, and may be d-form, l-form or dl-form. Of these, l-menthol is preferable. These monoterpenes can also be used for external patches as essential oils containing monoterpenes, such as eucalyptus oil, mint oil, clove oil, cinnamon oil, peppermint oil, mint oil, tea tree oil, chamomile Examples thereof include oil, rosemary oil, lemon oil, orange oil, thyme oil, sage oil, and clove oil. Eucalyptus oil, mint oil or tea tree oil is preferable, and eucalyptus oil or mint oil may be used in external patches. These monoterpenes can be used alone or in combination of two or more. The content of monoterpenes is usually 0.001 to 20% by weight, preferably 0.001 to 10% by weight, particularly preferably 0.01 to 5% by weight, based on the total weight of the plaster. it can.

[Adhesive]
Examples of the pressure-sensitive adhesive used in the present invention include a rubber-based pressure-sensitive adhesive, an acrylic pressure-sensitive adhesive, and a silicone-based pressure-sensitive adhesive. Examples of the rubber-based pressure-sensitive adhesive include natural rubber, synthetic rubber, styrene-isoprene-styrene block copolymer, isoprene rubber, polyisobutylene, styrene-butadiene-styrene block copolymer, styrene-butadiene rubber, and polybutene. Examples of the acrylic pressure-sensitive adhesive include homopolymers or copolymers of (meth) acrylic acid esters and / or copolymers of the above (meth) acrylic acid alkyl esters and other functional monomers. In the present specification, the term “(meth) acrylic acid” is used to mean acrylic acid or methacrylic acid (methacrylic acid). Thus, for example, the term (meth) acrylic acid ester means acrylic acid ester or methacrylic acid ester. Examples of the silicone-based pressure-sensitive adhesive include those containing polydimethylsiloxane as a main component. Among these pressure-sensitive adhesives, rubber-based pressure-sensitive adhesives are preferable in consideration of properties, manufacturing costs, ease of quality design, reproducibility, etc., and among them, styrene-isoprene-styrene block copolymers are more preferable. It is. These pressure-sensitive adhesives may be used alone or in combination of two or more. The amount of the pressure-sensitive adhesive is preferably 10 to 80% by weight based on the weight of the entire composition of the paste layer in consideration of the formation of the paste layer and the permeability of the active ingredient to the skin. More preferably, it is 20 to 40% by weight.

  In addition, as said styrene-isoprene-styrene block copolymer, TR-2000, TR-2003, SIS-5002, 5200 (trade name: JSR Corporation), Quintac 3421, 3520, 3530, 3570C (trade name: Zeon Corporation), Clayton D-KX401CS, D-1107CP, D-1161JP, D-6117 (trade name: JSR Kraton Elastomer Co., Ltd.), Sorprene 428 (trade name: Philippe Petroleum Corporation), etc. Species or a combination of two or more can be used.

[Thickness]
The total thickness of the support and plaster layer of the present invention is preferably 10 to 60 μm. If the thickness is less than 10 μm, there is a problem that the plaster layer cannot be formed satisfactorily due to the balance with the thickness of the support, and if it exceeds 60 μm, it is not satisfactory from the viewpoint of sticking feeling (uncomfortable feeling).

[Optional ingredients]
In the plaster layer of the patch of the present invention, as an optional component, a drug solubilizer, a transdermal absorption accelerator, a tackifier, a plasticizer, an excipient, an antioxidant, a fragrance, a colorant, water Etc. can be contained.

(Drug dissolution agent, transdermal absorption enhancer)
Examples of drug solubilizers and transdermal absorption enhancers used in the present invention include aliphatic carboxylic acids (acetic acid, propionic acid, oleic acid, linoleic acid, linolenic acid, isostearic acid, myristic acid, lauric acid, citric acid (anhydrous anhydride). (Including citric acid), organic acids such as isobutyric acid, caproic acid, caprylic acid, lactic acid, maleic acid, pyruvic acid, oxalic acid, succinic acid, tartaric acid), polyethylene glycol (also referred to as macrogol) (average molecular weight is 200) To 30000), polyhydric alcohols such as glycerin, ethylene glycol, diethylene glycol, fatty acid esters such as isopropyl myristate, isopropyl palmitate, diisopropyl adipate, diethyl sebacate, caprylic acid monoglyceride, caprylic acid triglyceride, sorbitan fatty acid ester, etc. Fat Acid polyhydric alcohol ester, N- methyl-2-pyrrolidone, and a crotamiton. Since these solubilizers and percutaneous absorption enhancers may affect the deterioration of the polyurethane film as a support, it is preferable to make the content as small as possible. For example, it is preferably 10% by weight or less.

(Tackifier)
Although it does not specifically limit as a tackifier used for this invention, A terpene resin, an alicyclic saturated hydrocarbon resin (synthetic petroleum resin), a rosin ester derivative, a phenol resin, etc. are mentioned. Examples of the terpene resin include YS resin PX-1150N (trade name: Yasuhara Chemical Co., Ltd.). Examples of the alicyclic saturated hydrocarbon resin include Alcon P-100 (trade name: Arakawa Chemical Industries, Ltd.). Examples of rosin ester derivatives include ester gum H (trade name: Arakawa Chemical Industries, Ltd.), KE-311 (trade name: Arakawa Chemical Industries, Ltd.), and KE-100 (trade name: Arakawa Chemical Industries, Ltd.). Can be mentioned. As a tackifier used for this invention, these 1 type (s) or 2 or more types can be selected and used, for example. Although content of a tackifier is not specifically limited, It is preferable that it is 10-35 mass% with respect to the whole plaster.

(Plasticizer)
The plasticizer used in the present invention is not particularly limited, and examples thereof include higher alcohols such as liquid paraffin and octyldodecanol, squalane, squalene and castor oil. Preferably, it is a liquid paraffin. Although content of a plasticizer is not specifically limited, Generally it is 20 to 60 weight% with respect to the whole plaster.

(Excipient)
Examples of the excipient used in the present invention include silicon compounds such as talc, silicic anhydride, light anhydrous silicic acid, and hydrous silicic acid, cellulose derivatives such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and polyvinyl alcohol. Water-soluble polymers such as dry aluminum hydroxide gel, hydrated aluminum silicate such as aluminum silicate, kaolin, titanium oxide and the like.

(Antioxidant)
Examples of the antioxidant used in the present invention include dibutylhydroxytoluene, ascorbic acid, tocopherol, tocopherol ester derivatives, butylhydroxyanisole and the like.

[liner]
The external patch of the present invention comprises a support that is a polyurethane film and a paste layer in which a paste is laminated on the support, and usually includes a peelable liner on the paste layer. Provided in. As the releasable liner, polyethylene, polypropylene, ethylene vinyl acetate copolymer, vinyl chloride film, aluminum-deposited metallic film, or the like can be used. Further, a liner surface that has been subjected to a peeling treatment such as a silicon treatment may be used. Moreover, it is preferable that the liner is provided with a cut portion such as a straight line or a curved shape in terms of easy peeling. As the installation method of the cut portion, two cut lines are provided to form a three-part liner. Also good.

[Production method]
As a method for producing an external patch of the present invention, the components to be included in the paste layer such as the drug and base component are heated and melted, and the melt is spread on a release liner to form a paste layer. It is preferable to use a method of obtaining an external patch by laminating a support, that is, a hot melt method. For example, the components to be included in the paste layer such as the drug and base component are dissolved in an organic solvent such as ethyl acetate, hexane, and toluene, and this dissolved product is spread on a release liner, and the solvent in the dissolved product is retained. After forming the plaster layer, the method for obtaining an external patch by pasting the support, that is, compared to the solvent method, the plaster layer may contain monoterpenes that are volatile components. This is because it is easy.

  EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.

An external patch was produced by the following composition and production method.
(composition)
(1) Felbinac 3.5% by weight
(2) 3.0% by weight of 1-menthol
(JP)
(3) Dibutylhydroxytoluene 0.5% by weight
(Medicine regulations)
(4) Talc 2.5% by weight
(JP)
(5) Styrene-isoprene-styrene block copolymer 30.0% by weight
(Medicine regulations)
(6) Terpene resin 17.0% by weight
(Medicine regulations)
(7) Liquid paraffin 43.5% by weight
(JP)
(Manufacturing method)
Each component except the compositions (1) and (2) was heated and melted, and then (1) and (2) were added and mixed and stirred to obtain a uniform melt. This melt was uniformly spread on a liner (PET film) at a rate of 70 cm ² per gram to form a paste layer. Thereafter, a polyurethane film (thickness: 8 μm) was bonded to the plaster layer to obtain an external patch of the present invention. The total thickness of the polyurethane film and the plaster layer was 20 μm.

An external patch of the present invention was produced according to the production method of Example 1 with the following formulation.
(1) Ketoprofen 2.0% by weight
(2) 2.0% by weight of 1-menthol
(JP)
(3) Dibutylhydroxytoluene 0.5% by weight
(Medicine regulations)
(4) Styrene-isoprene-styrene block copolymer 33.0% by weight
(Medicine regulations)
(5) Terpene resin 16.0% by weight
(Medicine regulations)
(6) Squalane 3.5% by weight
(External rule)
(7) Diethyl sebacate 0.5 wt%
(Medicine regulations)
(8) Liquid paraffin 42.5% by weight
(JP)

An external patch was produced by the following composition and production method.
(composition)
(1) Diclofenac sodium 1.0% by weight
(2) 2.0% by weight of 1-menthol
(JP)
(3) Dibutylhydroxytoluene 0.5% by weight
(Medicine regulations)
(4) Styrene-isoprene-styrene block copolymer 33.0% by weight
(Medicine regulations)
(5) Terpene resin 19.0% by weight
(Medicine regulations)
(6) Synthetic squalane 3.7% by weight
(Norimoto)
(7) Talc 2.5% by weight
(JP)
(8) Isostearic acid 5.0% by weight
(Medicine regulations)
(9) Liquid paraffin 33.3% by weight
(JP)
(Manufacturing method)
Each component except the compositions (1) and (2) was heated and melted, and then (1) and (2) were added and mixed and stirred to obtain a uniform melt. This melt was uniformly spread on a liner (PET film) at a rate of 70 cm ² per 1.5 g to form a paste layer. Thereafter, a polyurethane film (thickness: 8 μm) was bonded to the plaster layer to obtain an external patch of the present invention. The total thickness of the polyurethane film and the plaster layer was 20 μm.

An external patch of the present invention was produced according to the production method of Example 1 with the following formulation.
(1) Loxoprofen sodium dihydrate 5.67% by weight
(2) l-Menthol 3.00% by weight
(JP)
(3) Isostearic acid 5.00% by weight
(Medicine regulations)
(4) Dibutylhydroxytoluene 0.20% by weight
(Medicine regulations)
(5) Talc 2.50% by weight
(JP)
(6) Styrene-isoprene-styrene block copolymer 30.00% by weight
(Medicine regulations)
(7) Terpene resin 18.00% by weight
(Medicine regulations)
(8) Liquid paraffin 35.63 wt%
(JP)

An external patch of the present invention was produced according to the production method of Example 1 with the following formulation.
(1) Loxoprofen sodium dihydrate 5.67% by weight
(2) l-Menthol 3.00% by weight
(JP)
(3) Isostearic acid 5.00% by weight
(Medicine regulations)
(4) Macrogol 300 2.50% by weight
(Medicine regulations)
(5) Dibutylhydroxytoluene 0.20% by weight
(Medicine regulations)
(6) Talc 2.50% by weight
(JP)
(7) Styrene-isoprene-styrene block copolymer 30.00% by weight
(Medicine regulations)
(8) Terpene resin 18.00% by weight
(Medicine regulations)
(9) Liquid paraffin 33.13 wt%
(JP)

An external patch of the present invention was produced according to the production method of Example 1 with the following formulation.
(1) Loxoprofen sodium dihydrate 5.67% by weight
(2) l-Menthol 3.00% by weight
(JP)
(3) Isostearic acid 5.00% by weight
(Medicine regulations)
(4) Diisopropyl sebacate 5.00% by weight
(Medicine regulations)
(5) Dibutylhydroxytoluene 0.50% by weight
(Medicine regulations)
(6) Talc 2.50% by weight
(JP)
(7) Styrene-isoprene-styrene block copolymer 32.00% by weight
(Medicine regulations)
(8) Terpene resin 19.00% by weight
(Medicine regulations)
(9) Liquid paraffin 27.33% by weight
(JP)

<Comparative Example 1>
An external patch was prepared in the same procedure as in Example 1 except that 1-menthol was not added and 46.5% by weight of liquid paraffin was blended.

<Comparative Example 2>
An external patch was produced in the same manner as in Example 1 except that 10% by weight of N-methyl-2-pyrrolidone was added and 16.5% by weight of liquid paraffin was added without adding 1-menthol.

<Comparative Example 3>
An external patch was produced in the same procedure as in Example 3, except that a polyester knitted fabric having a thickness of 500 μm and a weight per unit area of 100 g / m ² was used in place of the polyurethane film.

<Evaluation>
About the external patch manufactured in the said Example 1, Example 3, and Comparative Examples 1-3, the property stability (plaster layer, support body), adhesiveness, and usability | use_condition of a formulation were evaluated.

[Test Example 1 (Property stability of formulation (plaster layer))]
The external patch (7 × 10 cm) produced in Example 1 and Comparative Example 1 was immediately sealed in an aluminum laminate packaging bag and then stored at 40 ° C. for 10 days. Thereafter, the presence or absence of precipitates in the plaster layer was visually observed and evaluated based on the following criteria. The results are shown in Table 1.
"Evaluation criteria for the presence or absence of precipitates"
○: No precipitate.
X: Precipitation exists.

[Test Example 2 (Property stability of preparation (support))]
The external patch (7 × 10 cm) produced in Example 1 and Comparative Example 2 was immediately sealed in an aluminum laminate packaging bag and then stored at 40 ° C. for 10 days. Thereafter, each external patch was applied to the subject's arm. Based on the following criteria, the presence or absence of deterioration of the support (polyurethane film) was visually observed and evaluated. The results are shown in Table 2.
"Evaluation criteria for deterioration of support"
○: Attached without problems.
X: The patch was torn and could not be applied.

[Test Example 3 (Adhesion, Usability)]
The external patch (7 × 10 cm) produced in Example 3 and Comparative Example 3 was applied to the subject's knee for 8 hours (no restriction on bending and stretching of the knee during working hours). Based on the following criteria, adhesion and usability were evaluated. The results are shown in Table 3.
"Evaluation criteria for adhesion and usability"
○: The patch was familiar with the skin surface and did not feel uncomfortable.
X: The patch did not conform to the skin surface, and a sense of incongruity was felt.

  The external patch of the present invention is a preparation that is excellent in property stability of the preparation, such as it is difficult to peel off sufficiently to the skin, has a good sticking feeling (no discomfort), and can suppress deterioration of the support. It can be suitably used as an external medicine.

Claims (2)

A support and a plaster layer laminated on the support;
The support is a polyurethane film having a thickness of 5 to 30 μm,
The total thickness of the support and the plaster layer is 10 to 60 μm,
The plaster layer comprises a drug, 1-menthol, and a styrene-isoprene-styrene block. Containing a polymer,
The drugs are felbinac, diclofenac, loxoprofen, ketoprofen, and It is at least one selected from the group consisting of these pharmacologically acceptable salts. A featured external patch. The external patch according to claim 1, wherein the paste layer further contains a terpene resin.